Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy, privileged insights into optimal therapeutic selection based on the latest clinical trial data, and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.
Upon completion of this activity, participants should be better able to:
Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology
Chief, Medical Oncology
Yale Cancer Center and Smilow Cancer Hospital
Associate Cancer Center Director, Translational Research
Yale Cancer Center
New Haven, CT
Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT
Head, Fingerland Department of Pathology
Charles University, Medical Faculty
Hradec Králové, Czech Republic
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources